Mojun Zhu is an Oncology physician. OpenAlex indexes 116 publications with 466 citations (h-index 8); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 852595499
Telephone
480-301-8000Provider last certified this registry record 29 Apr 2026.
Clinical trials
- A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
Sponsor: Mayo Clinic
Overall officialPhase 1CompletedNCT05130060 - Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Sponsor: Mayo Clinic
Overall officialPhase 1Active, not recruitingNCT04007744
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Astellas Pharma US IncProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
75.4%PD-1 inhibitor24.6%Pembrolizumab100%Part B, office-administered≥39 patientsCD38-directed Cytolytic Antibody22.2%Daratumumab100%Part B, office-administered≥43 patients+ 6 more classes in this area
Metabolism & gastrointestinal
21.3%Other antiemetics15.7%Fosaprepitant100%Part B, office-administered≥37 patientsSerotonin-3 Receptor Antagonist4%Palonosetron hcl62%Ondansetron hydrochloride37%Ondansetron Hcl2%Part D + Part B≥87 patients+ 2 more classes in this area
Sensory organs
2.9%Corticosteroid2.9%Dexamethasone sodium phosphate95%Dexamethasone5%Part D + Part B≥93 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”